| Literature DB >> 32567808 |
Szimonetta Eitmann1, Dávid Németh1, Péter Hegyi1, Zsolt Szakács1,2, András Garami3, Márta Balaskó1, Margit Solymár1, Bálint Erőss1,4, Enikő Kovács1, Erika Pétervári1.
Abstract
This systematic review and meta-analysis aimed to investigate the association between maternal overnutrition and offspring's insulin sensitivity-following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Studies published in English before April 22, 2019, were identified through searches of four medical databases. After selection, 15 studies aiming to explore the association between prepregnancy body mass index (ppBMI) or gestational weight gain (GWG) of non-diabetic mothers and their offspring's insulin sensitivity (fasting insulin or glucose level and Homeostatic Measurement Assessment for Insulin Resistance [HOMA-IR]) were included in the meta-analysis. Associations of ppBMI and GWG with offspring's insulin sensitivity were analysed by pooling regression coefficients or standardized differences in means with 95% confidence intervals (CIs). Maternal ppBMI showed significant positive correlations with the level of both fasting insulin and HOMA-IR in offspring (standardized regression coefficient for fasting insulin: 0.107, CI [0.053, 0.160], p < 0.001 and that for HOMA-IR: 0.063, CI [0.006, 0.121], p = 0.031). However, the result of the analysis on coefficients adjusted for offspring's actual anthropometry (BMI and adiposity) was not significant. Independent from ppBMI, GWG tended to show a positive correlation with insulin level, but not after adjustment for offspring's anthropometry. Offspring of mothers with excessive GWG showed significantly higher HOMA-IR than those of mothers with optimal GWG (p = 0.004). Our results demonstrate that both higher ppBMI and GWG increase the risk of offspring's insulin resistance, but the effect of ppBMI on insulin sensitivity in offspring may develop as consequence of their adiposity.Entities:
Keywords: gestational weight gain; insulin resistance; insulin sensitivity; prepregnancy BMI
Mesh:
Year: 2020 PMID: 32567808 PMCID: PMC7503101 DOI: 10.1111/mcn.13031
Source DB: PubMed Journal: Matern Child Nutr ISSN: 1740-8695 Impact factor: 3.092
FIGURE 1Flowchart of the study selection process
Characteristics of the included studies
| Author, year, country | Study design | Maternal characteristics | Offspring's characteristics | ||||
|---|---|---|---|---|---|---|---|
| Age | Sample size | ppBMI assessment | GWG assessment | Age | Male (%) | ||
| Brandt et al., | Prospective | 32.7 (32.4–33.0) | 249 | Records | Total GWG: Records | 8 | 49.3 |
| Dello Russo et al., | Retrospective | 28.4 (28.2–28.6) | 2,180 | Total GWG: Self‐reported | 2–9 | 52.8 | |
| Derraik et al., | Retrospective | 17–42 | 70 | Self‐reported weight | 4–11 | 61 | |
| Gaillard et al., | Prospective | 30.3 ± 5.1 | 3,877 (GWG in unadjusted model: 2640) | Self‐reported/measured weight | Maximum GWG: Self‐reported/measured | 5.6–8 | 49.9 |
| Gaillard et al., | Prospective | 29 ± 5.8 | 1,392 | Self‐reported weight | Total GWG: Measured | 16.7–17.7 | 50.7 |
| Hochner et al., | Prospective | 28.4 ± 5.5 | 1,134 | Self‐reported weight | Maximum GWG: Records | 32 ± 0 | 49.5 |
| Hrolfsdottir et al., | Prospective | 29.0 ± 4.9 | 308 | Maximum GWG: Records | 22.3 ± 3.0 | 39.3 | |
| Jeffery et al., | Prospective | 34 | 230 | Self‐reported weight | 8 ± 0 | 53.3 | |
| Maftei et al., | Prospective | 30.3 ± 5.1 | 163 | Self‐reported weight | Total GWG: Records | 9–10 | 45 |
| Mingrone et al., | Retrospective | 21–29 | 52 | Self‐reported weight | 23.8 ± 4.5 | 40 | |
| Oostvogels et al., | Prospective | 31.1 ± 4.7 | 1,459 | Self‐reported weight | 5–6 | 53 | |
| Perng et al., | Prospective | 15–44 |
677 (adjusted model) 592 (unadjusted model) | Self‐reported weight | Total GWG: Records | 7.7 (6.6–10.9) | 49.7 |
| Sauder et al., | Prospective | 30.0 ± 5.4 | 236 | Records | 16.6 ± 1.2 | 51 | |
| Tam et al., | Prospective | 31.3 ± 4.6 | 371 | Total GWG: Records | 7 ± 0 | 52 | |
| Winham et al., | Retrospective | 21.8 ± 1.7 | 8 | Total GWG: Records | 0.5 ± 0 | 56 | |
Abbreviations: GWG, gestational weight gain; ppBMI, prepregnancy BMI.
Age is expressed in mean ± standard deviation or range or median (interquartile range).
FIGURE 2Beta regression coefficients describing the association between prepregnancy body mass index (BMI) and offspring's insulin level without (upper panel; heterogeneity: I 2 = 71.81%, p = 0.014) or with adjustment for offspring's BMI (lower panel; I 2 = 40.32%, p = 0.187). Black squares show beta values with the area reflecting the weight assigned to the individual studies. Horizontal bars indicate 95% confidence intervals. Diamonds show the overall point estimate with 95% confidence intervals
FIGURE 3Beta regression coefficients describing the association between prepregnancy body mass index and offspring's Homeostatic Measurement Assessment for Insulin Resistance (HOMA‐IR) without (upper panel; heterogeneity: I 2 = 89.15%, p < 0.001) or with adjustment for offspring's anthropometry (lower panel; I 2 = 93.27%, p < 0.001). Black squares show beta values with the area reflecting the weight assigned to the individual studies. Horizontal bars indicate 95% confidence intervals. Diamonds show the overall point estimate with 95% confidence intervals
FIGURE 4Beta regression coefficients describing the association between gestational weight gain and offspring's insulin level without (upper panel; heterogeneity: I 2 = 0%, p = 0.992) or with adjustment for offspring's body mass index (lower panel; I 2 = 22.85%, p = 0.274). Black squares show beta values with the area reflecting the weight assigned to the individual studies. Horizontal bars indicate 95% confidence intervals. Diamonds show the overall point estimate with 95% confidence intervals
FIGURE 5Standardized differences in mean Homeostatic Measurement Assessment for Insulin Resistance (HOMA‐IR) values in offspring of mothers with excessive gestational weight gain (GWG) compared with those of adequate GWG. Black squares show the differences in mean values with the area reflecting the weight assigned to the individual studies. Horizontal bars indicate 95% confidence intervals. The diamond shows the overall point estimate with 95% confidence interval (heterogeneity: I 2 = 0%, p = 0.635)
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
|
| |||
| Title | 1 | Identify the report as a systematic review, meta‐analysis or both. | 1 |
|
| |||
| Structured summary | 2 | Provide a structured summary including, as applicable: Background; objectives; data sources; study eligibility criteria, participants and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
|
| |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3–4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS). | 4 |
|
| |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number. | 4 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow‐up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4–5, 29 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4, Appendix |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Appendix |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review and, if applicable, included in the meta‐analysis). | 4–5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4, Appendix |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 5 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 6–7 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., | 6–7 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta‐regression), if done, indicating which were pre‐specified. | 6 |
|
| |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 7, Figure |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow‐up period) and provide the citations. | 7–9, 29 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see Item 12). | 9, Appendix |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 10–12, Figures |
| Synthesis of results | 21 | Present results of each meta‐analysis done, including confidence intervals and measures of consistency. | 10–12, Figures |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 12 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta‐regression [see Item 16]). | 10–12 |
|
| |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users and policy makers). | 13–17 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). | 18 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 2, 18 |
|
| |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Title page |
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed1000097.
For more information, visit: www.prisma‐statement.org.
| Author, year, country | Study design | Maternal characteristics | Offspring | Reason of exclusion | ||||
|---|---|---|---|---|---|---|---|---|
| Age (year) | Sample size | Assessment | Age (year) | Outcome | ||||
| Unadjusted for offspring's anthropometry | Adjusted for offspring's anthropometry | |||||||
| Bucci et al., | Retrospective cohort | 22–34 (range) | 17 | Maternal groups based on BMI prior to delivery: ≥28.1 vs. ≤26.3 |
71.5 ± 0.9 (mean ± SD) | Higher level of: Insulin glucose muscle insulin sensitivity* | — | BMI assessed only prior to delivery |
| Eriksson et al., | Retrospective cohort | 22–34 (range) | 13,345 | Maternal groups based on BMI prior to delivery: ≥28 vs. ≤24 | 56–70 (range) | Higher OR for diagnosed diabetes mellitus Type 2* | ‐ | BMI assessed only prior to delivery |
| Mi et al., | Prospective cohort | 22–33 (range) | 627 | BMI as continuous variable | 43–46 (range) | — | Negative regression coefficient for glucose insulin* | BMI assessed only at 15th and 38th weeks of gestation |
| Shaikh et al., | Cross‐sectional | 25.23 ± 3.68 (mean ± SD) | 24 | Maternal groups based on BMI in the third trimester: <22 vs. >23 | Newborn | Higher level of insulin glucose* HOMA‐IR | — | BMI assessed between 28 and 40 weeks of gestation |
| Veena et al., | Prospective cohort | 23.5 ± 4.0 (mean ± SD) | 504 | BMI at 30th week of gestation as continuous variable | 9.5 | Positive sdr regression coefficient for insulin* glucose | Positive sdr regression coefficient for insulin HOMA‐IR negative regression coefficient for glucose | BMI assessed only at 30th week of gestation |
Abbreviations: BMI, body mass index; HOMA‐IR, Homeostatic Measurement Assessment for Insulin Resistance; IQR, interquartile range; SD, standard deviation; sdr, standardized.
* p < 0.05.
| Author, year, country | Adjustments with covariates |
|---|---|
| Brandt, 2014, Germany | Offspring: Gender. |
| Dello Russo et al., |
Mothers: Age, BMI, gestational age, alcohol, and smoking during pregnancy, gestational diabetes, hypertension. Offspring: Sex, age, practice of sport, breastfeeding duration. |
| Derraik et al., |
Mothers: Birth order, age. Offspring: Age, sex, birth weight. |
| Gaillard et al., |
Mothers: ppBMI, age, educational level, ethnicity, parity, gestational age, height, smoking, alcohol, calorie intake during pregnancy, folic acid supplement use, delivery mode. Offspring: Sex, age, breastfeeding duration, age at introduction of solid foods, duration of TV‐watching, with/without BMI. |
| Gaillard et al., |
Mothers: ppBMI, age, ethnicity, educational level, household income, parity, smoking during pregnancy, total GWG, hypertension, gestational diabetes, caesarean delivery, gestational age. Offspring: Sex, age, birth weight, and length, breastfeeding duration, infant length, and weight growth, paternal BMI, Tanner stage, smoking, alcohol, calorie intake, physical activity, with/without BMI. |
| Hochner et al., |
Mothers: Age, parity, smoking, socioeconomic status, years of education, medical condition, gestational week Offspring: Ethnicity, sex, birth weight, smoking, physical activity, years of education, with/without BMI |
| Hrolfsdottir et al., |
Mothers: ppBMI, age, parity, smoking, educational level. Offspring: Sex, whether offspring think their father is overweight. |
| Jeffery et al., | Unadjusted. |
| Maftei et al., |
Mothers: Gestational diabetes. Offspring: With/without z‐BMI. |
| Mingrone et al., | Unadjusted. |
| Oostvogels et al., |
Mothers: Age, height, education level, ethnicity, parity, hypertension, smoking during pregnancy, gestational age. Offspring: Sex, birth weight, breastfeeding duration, screen time per day, energy intake, with/without weight‐for‐length gain. |
| Perng et al., |
Mothers: ppBMI, race/ethnicity, parity, smoking, household income. Offspring: Sex, age, father's BMI, with/without DXA total fat mass index. |
| Sauder et al., | Offspring: Sex, race/ethnicity, age, Tanner stage, age by Tanner interaction, with/without BMI |
| Tam et al., |
Mothers: ppBMI, insulin sensitivity, parity, age, gestational age. Offspring: Sex, age, breastfeeding duration, exercise level. |
| Winham et al., | Unadjusted. |
Abbreviations: DXA, dual‐energy X‐ray absorptiometry; GWG, gestational weight gain; ppBMI, prepregnancy BMI.
| Modified QUIPS items | Brandt 2014 | Dello Russo 2013 | Derraik 2015 | Gaillard 2014 | Gaillard 2016 | Hochner 2012 | Hrolfsdottir 2015 | Jeffery 2006 | Maftei 2015 | Mingrone 2008 | Oostvogels 2014 | Perng 014 | Sauder 2017 | Tam 2018 | Winham 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Study participation | |||||||||||||||
| Source of target population adequately described for key characteristics including age, gender, pregnancy characteristics | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| The method used to identify the study population is described adequately | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Recruitment period is stated | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| Place of recruitment (setting and location) is stated | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Inclusion and exclusion criteria are clearly defined | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| There is adequate participation in the study by eligible individuals >80%a | No | NA | NA | No | No | No | No | Yes | No | NA | No | No | No | No | NA |
| Baseline characteristics of the participants are collected including gestational age, birth weight, age, gender | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Summary: Study participation | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Moderate |
| 2. Study attrition | |||||||||||||||
| All the included patients have outcome data, or the dropout rate is maximum 20%a | No | NA | NA | No | No | No | No | Yes | No | NA | No | No | No | No | NA |
| Attempts to collect information on participants who dropped outa | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | NA |
| Reasons for lost to follow‐up are describeda | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | NA |
| Key characteristics (age, gender, pregnancy characteristics) information on those lost to follow‐upa | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | NA |
| There are no important differences between key characteristics and outcomes in participants who completed the study and those who did nota | Unclear | NA | NA | Unclear | Unclear | Yes | Unclear | Unclear | Unclear | NA | Unclear | Unclear | Unclear | Unclear | NA |
| Summary: Study attrition | Moderate | NA | NA | Moderate | Moderate | Low | Moderate | Low | Moderate | NA | Moderate | Moderate | Moderate | Moderate | NA |
| 3. Prognostic factor measurement | |||||||||||||||
| Definition of maternal nutritional state (ppBMI and/or GWG) and the method of measurements are clearly described | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Method of measuring of maternal nutritional state is valid and reliableb | Yes | Partly | Partly | Partly | Partly | Partly | Yes | Partly | Partly | Partly | Partly | Partly | Yes | Yes | Yes |
| Continuous variables (ppBMI and/or GWG) are reported or appropriate cut points are used (GWG categories in accordance with the IOM recommendations) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Method and setting of measuring maternal nutritional state are the same for all study participants | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| All the included participants have complete data for the maternal nutritional state | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Appropriate method was used to replace the missing data on maternal nutritional statec | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Summary: Measurement of the maternal nutritional state | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low |
| 4. Outcome measurement | |||||||||||||||
| Definition of outcome: Fasting insulin level | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | NA | Yes | NA | NA | Yes | Yes | Yes |
| Definition of outcome: HOMA‐IR | NA | Yes | NA | NA | Yes | NA | Yes | Yes | Yes | NA | NA | Yes | Yes | Yes | NA |
| Definition of outcome: Fasting glucose level | NA | NA | NA | NA | Yes | Yes | Yes | NA | NA | NA | Yes | NA | NA | Yes | NA |
| Valid and reliable measurement of outcome | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Method and setting of outcome measurement is the same for all study participants | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Summary: Outcome measurement | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low |
| 5. Study confounding | |||||||||||||||
| Maternal age, as an important confounder is measured | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Maternal smoking habits during pregnancy, as an important confounder is measured | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes | No |
| Maternal socioeconomic status/maternal educational level, as an important confounder is measured | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | No | No |
| Birth weight, as an important confounder is measured | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes |
| Breastfeeding, as an important confounder is measured | No | Yes | No | Yes | Yes | No | No | No | No | No | Yes | Yes | No | Yes | No |
| Offspring's age, as an important confounder is measured | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Offspring's adiposity (weight or BMI or fat mass index), as an important confounder is measured | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| The measured confounding factors are clearly defined | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Valid and reliable measurement of confounders | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Method and setting of confounding measurement are the same for all study participants | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| An appropriate method was used for replacing missing confounder data (e.g., imputation) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Important confounders are accounted for in the study design (e.g., initial assembly of comparable groups or matching) | Partly | Yes | Partly | Yes | Yes | Partly | Partly | Partly | No | No | Yes | Yes | Partly | Partly | No |
| Confounders considered important by the authors of the article, are accounted for in the analysis (e.g., appropriate adjustment, stratification, multivariate regression) | No | Yes | No | Yes | Yes | Partly | No | No | No | No | Yes | Partly | No | Partly | No |
| Summary: Study confounding | High | Low | High | Low | Low | Moderate | High | High | High | High | Low | Moderate | High | High | High |
| 6. Statistical analysis and reporting | |||||||||||||||
| The analytical strategy is described in detail, the adequacy of the analysis can be judged | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Strategy for model building is appropriate and is based on a conceptual framework or model | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| The results are reported in detail, no selective reporting can be observed | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear | Yes | Unclear | Unclear | Yes | Yes | Yes | Yes | Unclear |
| Summary: Statistical analysis and presentation | Low | Low | Moderate | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low | Low |
Ratings: Items are rated with yes (low risk of bias), unclear (unknown risk of bias), partly (moderate risk of bias) or no (high risk of bias).
For the 1st–4th and the 6th domains: If two of the items were rated as unclear, partly or no, then the specific main domain was considered to carry moderate risk of bias. If three or more of the items were rated as unclear, partly or no, then the specific main domain was considered to be carrying high risk of bias. Because the reasons for lost to follow‐up (dropouts) were described in all prospective studies and they randomly affected the participants, the dropout rate higher than 20% was unlikely to cause selection bias (see domains 1st and 2nd).
For the 5th domain: If maximum one of the items was rated as no plus one or two were rated as partly, then the specific main domain was considered to be carrying moderate risk of bias. If two or more of the items was rated as no, then the specific main domain was considered to be carrying high risk of bias.
Abbreviations: BMI, body mass index; GWG, gestational weight gain; HOMA‐IR, Homeostatic Measurement Assessment for Insulin Resistance; IOM, Institute of Medicine; NA, not applicable due to study design; ppBMI, prepregnancy BMI.
Items only applicable in case of prospective studies. Retrospective ones were not assessed.
In case of self‐reported maternal data the item was rated as partly. If data were measured or obtained from records, the item was rated as yes.
Only those patients were included in the studies, who had appropriate data on maternal nutritional state. Therefore, this item was not assessed.